We are live on ! Find out more
ZBIO

Zenas BioPharma
ZBIO

73 hedge funds and large institutions have $330M invested in Zenas BioPharma in 2025 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 34 increasing their positions, 12 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

183% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 12

120% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 5

29% more capital invested

Capital invested by funds: $257M → $330M (+$73.3M)

9% more funds holding

Funds holding: 67 → 73 (+6)

3.66% more ownership

Funds ownership: 77.75% → 81.41% (+3.7%)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

Holders
73
Holders Change
+6
Holders Change %
+8.96%
% of All Funds
0.96%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
11
Increased
34
Reduced
12
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Federated Hermes
Federated Hermes
Pennsylvania
+$6.85M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$4.59M
3
Citadel Advisors
Citadel Advisors
Florida
+$2.86M
4
SAM
Sectoral Asset Management
Quebec, Canada
+$2.05M
5
NMC
NEA Management Company
Maryland
+$1.17M

Top Sellers

Rank Fund Capital Flow
1
RSCM
Rock Springs Capital Management
Maryland
-$2.32M
2
EP
Eversept Partners
New York
-$1.17M
3
CCM
Catalio Capital Management
New York
-$777K
4
JFG
Jefferies Financial Group
New York
-$348K
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$316K
Name Holding Trade Value Shares
Change 		Change in
Stake
Charles Schwab
26
Charles Schwab
California
$1.18M +$59.1K +6,070 +5%
Northern Trust
27
Northern Trust
Illinois
$1.16M -$7.04K -723 -0.6%
SCM
28
Superstring Capital Management
New York
$1.08M – – –
Bank of New York Mellon
29
Bank of New York Mellon
New York
$372K +$31.6K +3,245 +9%
N
30
Nuveen
North Carolina
$306K – – –
Barclays
31
Barclays
United Kingdom
$270K +$113K +11,653 +72%
AQR Capital Management
32
AQR Capital Management
Connecticut
$239K +$240K +24,668 New
UBS Group
33
UBS Group
Switzerland
$235K +$34.1K +3,498 +17%
AA
34
ALPS Advisors
Colorado
$219K -$54.3K -5,579 -20%
RhumbLine Advisers
35
RhumbLine Advisers
Massachusetts
$191K +$79.9K +8,207 +71%
Two Sigma Investments
36
Two Sigma Investments
New York
$190K +$191K +19,617 New
Susquehanna International Group
37
Susquehanna International Group
Pennsylvania
$189K +$8.8K +904 +5%
BC
38
Birchview Capital
Vermont
$160K – – –
AllianceBernstein
39
AllianceBernstein
Tennessee
$159K +$159K +16,360 New
UBS AM
40
UBS AM
Illinois
$144K +$145K +14,900 New
Bank of America
41
Bank of America
North Carolina
$136K +$33.2K +3,412 +32%
IIM
42
INTECH Investment Management
Florida
$128K +$15.7K +1,607 +14%
AGM
43
Alpine Global Management
New York
$125K +$126K +12,907 New
SEI Investments
44
SEI Investments
Pennsylvania
$118K +$1.81K +186 +2%
Wells Fargo
45
Wells Fargo
California
$101K +$22K +2,261 +28%
MIM
46
MetLife Investment Management
New Jersey
$97.9K +$127 +13 +0.1%
PNC Financial Services Group
47
PNC Financial Services Group
Pennsylvania
$88.9K +$26.1K +2,679 +41%
Mirae Asset Global ETFs Holdings
48
Mirae Asset Global ETFs Holdings
Hong Kong
$86.1K -$974 -100 -1%
JP Morgan Chase
49
JP Morgan Chase
New York
$74.4K +$3.98K +409 +6%
New York State Common Retirement Fund
50
New York State Common Retirement Fund
New York
$60.1K – – –
1
2
3 4

ZBIO Hedge Fund Activity: Q2 2025 in Review

73 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Zenas BioPharma (ZBIO) for Q2 2025, worth a combined $330M — up 29% from $257M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new ZBIO positions and 5 closed out — a net gain of 6 holders — while 34 added to existing stakes and 12 trimmed.

The largest buyer was Federated Hermes, adding an estimated $6.85M. The largest seller was Rock Springs Capital Management, cutting an estimated $2.32M.

  • 73 institutional investors held Zenas BioPharma (ZBIO) as of Q2 2025, up from 67 in Q1 2025.
  • Funds reported $330M of Zenas BioPharma stock for Q2 2025, up 29% quarter-over-quarter.
  • 11 funds opened new Zenas BioPharma positions in Q2 2025 and 5 closed out, a net change of +6 holders.
  • The largest Zenas BioPharma buyer in Q2 2025 was Federated Hermes, an estimated $6.85M added.
  • The largest Zenas BioPharma seller in Q2 2025 was Rock Springs Capital Management, an estimated $2.32M sold.

Based on aggregated 13F filings for Q2 2025.